Biogen Hires Pfizer Neuroscientist Michael Ehlers as R&D Chief
- CEO says company to boost $2 billion R&D budget in the future
- Pipeline includes drugs for Alzheimer's, multiple sclerosis
This article is for subscribers only.
Biogen Inc. has hired Pfizer Inc.’s Michael Ehlers to be its new research and development chief, filling a vacancy at the biotechnology company that has been open for nine months.
Ehlers, 47, will join Cambridge, Massachusetts-based Biogen in late May, the company said Wednesday in a statement. Ehlers was Pfizer’s group senior vice president for biotherapeutics R&D and chief scientific officer for the company’s neuroscience and pain research unit, which included work on programs in Alzheimer’s disease, Parkinson’s disease and schizophrenia. Before that, he was a neurobiology professor at Duke University Medical Center.